Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research note issued to investors on Wednesday,Benzinga reports. They currently have a $42.00 price objective on the biotechnology company's stock. HC Wainwright's price objective indicates a potential upside of 348.24% from the company's current price.
Several other equities research analysts also recently issued reports on the stock. D. Boral Capital reaffirmed a "buy" rating and set a $46.00 price target on shares of Anavex Life Sciences in a research note on Wednesday. Wall Street Zen downgraded shares of Anavex Life Sciences from a "hold" rating to a "sell" rating in a research note on Saturday, August 23rd. Two research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $44.00.
Get Our Latest Research Report on AVXL
Anavex Life Sciences Stock Down 2.2%
Shares of AVXL stock traded down $0.21 during mid-day trading on Wednesday, reaching $9.37. The company's stock had a trading volume of 714,428 shares, compared to its average volume of 951,523. Anavex Life Sciences has a 12-month low of $5.03 and a 12-month high of $14.44. The firm has a market capitalization of $804.79 million, a PE ratio of -16.44 and a beta of 0.83. The company's 50 day simple moving average is $10.47 and its 200-day simple moving average is $9.33.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last released its quarterly earnings results on Tuesday, August 12th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.03). As a group, research analysts anticipate that Anavex Life Sciences will post -0.69 EPS for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the business. PVG Asset Management Corp boosted its holdings in shares of Anavex Life Sciences by 34.9% in the 2nd quarter. PVG Asset Management Corp now owns 111,445 shares of the biotechnology company's stock valued at $1,028,000 after buying an additional 28,837 shares during the period. State of Wyoming acquired a new position in shares of Anavex Life Sciences in the 2nd quarter valued at about $26,000. Tower Research Capital LLC TRC boosted its holdings in shares of Anavex Life Sciences by 215.7% in the 2nd quarter. Tower Research Capital LLC TRC now owns 13,850 shares of the biotechnology company's stock valued at $128,000 after buying an additional 9,463 shares during the period. Ameriprise Financial Inc. boosted its holdings in shares of Anavex Life Sciences by 1.5% in the 2nd quarter. Ameriprise Financial Inc. now owns 85,990 shares of the biotechnology company's stock valued at $793,000 after buying an additional 1,233 shares during the period. Finally, Raymond James Financial Inc. boosted its holdings in shares of Anavex Life Sciences by 29.2% in the 2nd quarter. Raymond James Financial Inc. now owns 22,130 shares of the biotechnology company's stock valued at $204,000 after buying an additional 5,000 shares during the period. 31.55% of the stock is owned by institutional investors and hedge funds.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Recommended Stories
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
